Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 129

1.

Incidence and early outcomes associated with pre-transplant anti-vimentin antibodies in the cardiac transplantation population.

Young RK, Dale B, Russell SD, Zachary AA, Tedford RJ.

Clin Transplant. 2015 May 18. doi: 10.1111/ctr.12567. [Epub ahead of print]

PMID:
25982351
2.

HLA high-resolution typing for sensitized patients: a solution in search of a problem?

Cecka JM, Reed EF, Zachary AA.

Am J Transplant. 2015 Apr;15(4):855-6. doi: 10.1111/ajt.13169. Epub 2015 Mar 16. No abstract available.

PMID:
25778678
3.

Differences in immunogenicity of HLA antigens and the impact of cross-reactivity on the humoral response.

Lucas DP, Leffell MS, Zachary AA.

Transplantation. 2015 Jan;99(1):77-85. doi: 10.1097/TP.0000000000000355.

4.

Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation.

Orandi BJ, Zachary AA, Dagher NN, Bagnasco SM, Garonzik-Wang JM, Van Arendonk KJ, Gupta N, Lonze BE, Alachkar N, Kraus ES, Desai NM, Locke JE, Racusen LC, Segev DL, Montgomery RA.

Transplantation. 2014 Oct 27;98(8):857-63. doi: 10.1097/TP.0000000000000298.

PMID:
25121475
5.

A closer look at rituximab induction on HLA antibody rebound following HLA-incompatible kidney transplantation.

Jackson AM, Kraus ES, Orandi BJ, Segev DL, Montgomery RA, Zachary AA.

Kidney Int. 2015 Feb;87(2):409-16. doi: 10.1038/ki.2014.261. Epub 2014 Jul 23.

PMID:
25054778
6.

Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies.

Gupta G, Abu Jawdeh BG, Racusen LC, Bhasin B, Arend LJ, Trollinger B, Kraus E, Rabb H, Zachary AA, Montgomery RA, Alachkar N.

Transplantation. 2014 Jun 27;97(12):1240-6. doi: 10.1097/01.TP.0000442503.85766.91.

PMID:
24937198
7.

Quantifying the risk of incompatible kidney transplantation: a multicenter study.

Orandi BJ, Garonzik-Wang JM, Massie AB, Zachary AA, Montgomery JR, Van Arendonk KJ, Stegall MD, Jordan SC, Oberholzer J, Dunn TB, Ratner LE, Kapur S, Pelletier RP, Roberts JP, Melcher ML, Singh P, Sudan DL, Posner MP, El-Amm JM, Shapiro R, Cooper M, Lipkowitz GS, Rees MA, Marsh CL, Sankari BR, Gerber DA, Nelson PW, Wellen J, Bozorgzadeh A, Gaber AO, Montgomery RA, Segev DL.

Am J Transplant. 2014 Jul;14(7):1573-80. doi: 10.1111/ajt.12786. Epub 2014 Jun 9.

PMID:
24913913
8.

Differential effect of bortezomib on HLA class I and class II antibody.

Philogene MC, Sikorski P, Montgomery RA, Leffell MS, Zachary AA.

Transplantation. 2014 Sep 27;98(6):660-5. doi: 10.1097/TP.0000000000000132.

PMID:
24798311
9.

The role of donor-specific HLA alloantibodies in liver transplantation.

O'Leary JG, Demetris AJ, Friedman LS, Gebel HM, Halloran PF, Kirk AD, Knechtle SJ, McDiarmid SV, Shaked A, Terasaki PI, Tinckam KJ, Tomlanovich SJ, Wood KJ, Woodle ES, Zachary AA, Klintmalm GB.

Am J Transplant. 2014 Apr;14(4):779-87. doi: 10.1111/ajt.12667. Epub 2014 Mar 1.

10.

Time course of pathologic changes in kidney allografts of positive crossmatch HLA-incompatible transplant recipients.

Bagnasco SM, Zachary AA, Racusen LC, Arend LJ, Carter-Monroe N, Alachkar N, Nazarian SM, Lonze BE, Montgomery RA, Kraus ES.

Transplantation. 2014 Feb 27;97(4):440-5. doi: 10.1097/01.TP.0000437177.40551.f4.

PMID:
24531821
11.

Histologic phenotype on 1-year posttransplantation biopsy and allograft survival in HLA-incompatible kidney transplants.

Sharif A, Kraus ES, Zachary AA, Lonze BE, Nazarian SM, Segev DL, Alachkar N, Arend LJ, Bagnasco SM, Racusen LC, Montgomery RA.

Transplantation. 2014 Mar 15;97(5):541-7. doi: 10.1097/01.TP.0000442513.27641.7e.

PMID:
24521779
12.

Desensitization for solid organ and hematopoietic stem cell transplantation.

Zachary AA, Leffell MS.

Immunol Rev. 2014 Mar;258(1):183-207. doi: 10.1111/imr.12150. Review.

13.

Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation.

Lonze BE, Zachary AA, Magro CM, Desai NM, Orandi BJ, Dagher NN, Singer AL, Carter-Monroe N, Nazarian SM, Segev DL, Streiff MB, Montgomery RA.

Am J Transplant. 2014 Feb;14(2):459-65. doi: 10.1111/ajt.12540. Epub 2014 Jan 8.

14.

Red blood cell transfusions and the risk of allosensitization in patients awaiting primary kidney transplantation.

Leffell MS, Kim D, Vega RM, Zachary AA, Petersen J, Hart JM, Rossert J, Bradbury BD.

Transplantation. 2014 Mar 15;97(5):525-33. doi: 10.1097/01.tp.0000437435.19980.8f.

PMID:
24300013
15.

Time Course of Pathologic Changes in Kidney Allografts of Positive Crossmatch HLA-Incompatible Transplant Recipients.

Bagnasco SM, Zachary AA, Racusen LC, Arend LJ, Carter-Monroe N, Alachkar N, Nazarian SM, Lonze BE, Montgomery RA, Kraus ES.

Transplantation. 2013 Oct 29. [Epub ahead of print]

PMID:
24173106
16.

Transplanting the highly sensitized patient: trials and tribulations.

Iyer HS, Jackson AM, Zachary AA, Montgomery RA.

Curr Opin Nephrol Hypertens. 2013 Nov;22(6):681-8. doi: 10.1097/MNH.0b013e328365b3b9. Review.

PMID:
24076558
17.

Assessing immunologic risk factors in transplantation.

Philogene MC, Zachary AA.

Expert Rev Clin Immunol. 2013 Aug;9(8):773-9. doi: 10.1586/1744666X.2013.814413. Review.

PMID:
23971755
18.

Tetramer staining for the detection of HLA-specific B cells.

Lucas DP, Leffell MS, Zachary AA.

Methods Mol Biol. 2013;1034:313-8. doi: 10.1007/978-1-62703-493-7_17.

PMID:
23775745
19.

Transplantation of the sensitized patient: histocompatibility testing.

Montgomery RA, Leffell MS, Zachary AA.

Methods Mol Biol. 2013;1034:117-25. doi: 10.1007/978-1-62703-493-7_6.

PMID:
23775734
20.

Reply to "Defining the benefits of desensitization therapy".

Singer AL, Alachkar N, Montgomery RA, Zachary AA.

Transplantation. 2013 Mar 27;95(6):e33. doi: 10.1097/TP.0b013e3182845ffb. No abstract available.

PMID:
23507652
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk